查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1226716

临床障碍治疗的全球市场:现状分析、预测(2022年～2028年)

Clinical Disorder Treatment Market: Current Analysis and Forecast (2022-2028)
出版日期: | 出版商: UnivDatos Market Insights Pvt Ltd | 英文 154 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

全球临床障碍治疗的市场规模，与精神、心理疾病的盛行率同样，青春期的药物依赖症全球增加，以约6％稳定成长。还有许多医院，诊所，医疗机关，对一般大众实施临床疾病恰当治疗方法相关教育宣传活动，预计不久的将来，有带给市场很大成长的可能性。

本报告提供全球临床障碍治疗市场相关调查分析，各市场区隔、各地区的市场洞察，市场动态，市场趋势，竞争情形，企业简介等系统性资讯。

目录

第1章 市场简介

第2章 调查手法、前提条件

第3章 市场概要

第4章 摘要整理

第5章 COVID-19对临床障碍市场的影响

第6章 临床障碍市场收益(2020年～2028年)

第7章 市场洞察:各类药物

  • 抗忧郁症药
  • 抗痉挛药
  • 抗焦虑药
  • 非典型抗精神病药物
  • 去甲肾上腺素促效剂

第8章 市场洞察:各症状

  • 不安
  • 打

第9章 市场洞察:各药物销售管道

  • 院内药局
  • 零售药局
  • 线上药局

第10章 市场洞察:各地区

  • 北美
    • 美国
    • 加拿大
    • 其他北美
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 其他欧洲
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 其他亚太地区
  • 其他地区

第11章 临床障碍:市场动态

  • 推动市场要素
  • 市场课题
  • 影响分析

第12章 临床障碍:市场机会

第13章 临床障碍:市场趋势

第14章 需求侧、供给侧的分析

  • 需求面分析
  • 供给侧分析

第15章 价值链分析

第16章 价格分析

第17章 策略性举措

第18章 竞争模式

  • 竞争情形
    • 波特的五力分析

第19章 企业概要

  • Universal Health Services, Inc
  • CareTech Holdings Plc
  • Behavioral Health Network, Inc
  • Pfizer Inc
  • GSK Plc
  • Eli Lilly and Company
  • AstraZeneca Plc
  • Bristol-Myers Squibb Company
  • Johnson & Johnson Services, Inc
  • VistaGen Therapeutics, Inc

第20章 免责声明

简介目录
Product Code: UMME211603

Clinical Disorder treatment are focused on the diagnosis and treatment of psychiatric and psychological disorders. The main areas focus on mood disorders, anxiety disorders, obesity and eating disorders, addictions, and psychosomatic disorders. This illness can affect anyone, and of any age. This disorder is treatable. According to a statistical report by Global Burden of Diseases, Injuries, and Risk Factors Study 2017 (GBD 2017), 264 million people were affected by depression, whereas, dementia affected nearly 50 million people globally. This is in turn projected to offer abundant growth opportunities.

The clinical disorder treatment market is expected to grow at a steady rate of around 6% owing to the increasing use of adolescent substance addiction is on the rise globally, as is the prevalence of mental and psychological illnesses. Additionally, a lot of hospitals, clinics, and healthcare organizations are running campaigns to educate the general people about the proper course of treatment for clinical diseases. In turn, this is anticipated to provide the market with a wealth of growth potential in the near future.

Based on drug class, the market is segmented into antidepressants, anticonvulsants, anxiolytics, atypical antipsychotics, and noradrenergic agents. The antidepressants category held a significant share in 2020. An increasing number of candidates and product approvals of antidepressants will boost the market segment growth in the future due to rising hospital visits. Recently, the Food and Drug Administration (FDA) authorized two brand-new antidepressants that offer innovative methods for treating depression: esketamine and brexanolone.

Based on the indication, the market is categorized into anxiety and depression. This is mainly due to the influence of COVID-19 on the world which has been unparalleled and astounding, with increased demand shocks for anxiety disorders and depression treatment goods throughout all regions during the pandemic. During this time people are largely exposed to anxiety disorder. In addition, collaborative efforts by healthcare companies, NGOs, and government initiatives spreading awareness have become another factor in demand.

Based on the drug distribution channel, the market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment is predicted to grow at the fastest rate among all medication distribution channels over the course of the projection year.

For a better understanding of the market adoption of the clinical disorder treatment, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. The market in North America is anticipated to gain the major proportion throughout the projection period owing to the region's high healthcare spending and growing awareness of the signs and symptoms of clinical illnesses. Additionally, in the APAC region it is anticipated to grow at a substantial CAGR during the forecast period. This is mainly due to growing incidences of substance abuse among teenagers and adults, in the countries like India and China. In 2019, South Asia regions witness approximately 30 million people is exposed to cannabis and 22 million people consuming opioids. In the upcoming years, it is also anticipated that the region's industry will increase due to the strong presence of key market players.

Some of the major players operating in the market include: Universal Health Services Inc, CareTech Holdings plc, Behavioral Health Network Inc, Pfizer Inc, GSK plc, Eli Lilly and Company, Bristol-Myers Squibb Company, Johnson & Johnson Services Inc and VistaGen Therapeutics Inc.

TABLE OF CONTENTS

1 MARKET INTRODUCTION

  • 1.1. Market Definitions
  • 1.2. Main Objective
  • 1.3. Stakeholders
  • 1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

  • 2.1. Research Process of the Clinical Disorder Treatment Market
  • 2.2. Research Methodology of the Clinical Disorder Treatment Market
  • 2.3. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 IMPACT OF COVID-19 ON THE CLINICAL DISORDER MARKET

6 CLINICAL DISORDER MARKET REVENUE (USD BN), 2020-2028F

7 MARKET INSIGHTS BY DRUG CLASS

  • 7.1. Antidepressants
  • 7.2. Anticonvulsants
  • 7.3. Anxiolytics
  • 7.4. Atypical Antipsychotics
  • 7.5. Noradrenergic agents

8 MARKET INSIGHTS BY INDICATION

  • 8.1. Anxiety
  • 8.2. Depression

9 MARKET INSIGHTS BY DRUG DISTRIBUTION CHANNEL

  • 9.1. Hospital Pharmacy
  • 9.2. Retail Pharmacy
  • 9.3. Online Pharmacy

10 MARKET INSIGHTS BY REGION

  • 10.1. North America
    • 10.1.1. USA
    • 10.1.2. Canada
    • 10.1.3. Rest of North America
  • 10.2. Europe
    • 10.2.1. Germany
    • 10.2.2. U.K.
    • 10.2.3. France
    • 10.2.4. Italy
    • 10.2.5. Spain
    • 10.2.6. Rest of Europe
  • 10.3. Asia-Pacific
    • 10.3.1. China
    • 10.3.2. Japan
    • 10.3.3. India
    • 10.3.4. Rest of Asia-Pacific
  • 10.4. Rest of World

11 CLINICAL DISORDER MARKET DYNAMICS

  • 11.1. Market Drivers
  • 11.2. Market Challenges
  • 11.3. Impact Analysis

12 CLINICAL DISORDER MARKET OPPORTUNITIES

13 CLINICAL DISORDER MARKET TRENDS

14 DEMAND AND SUPPLY-SIDE ANALYSIS

  • 14.1. Demand Side Analysis
  • 14.2. Supply Side Analysis

15 VALUE CHAIN ANALYSIS

16 PRICING ANALYSIS

17 STRATEGIC INITIATIVES

18 COMPETITIVE SCENARIO

  • 18.1. Competitive Landscape
    • 18.1.1. Porters Fiver Forces Analysis

19 COMPANY PROFILED

  • 19.1. Universal Health Services, Inc
  • 19.2. CareTech Holdings Plc
  • 19.3. Behavioral Health Network, Inc
  • 19.4. Pfizer Inc
  • 19.5. GSK Plc
  • 19.6. Eli Lilly and Company
  • 19.7. AstraZeneca Plc
  • 19.8. Bristol-Myers Squibb Company
  • 19.9. Johnson & Johnson Services, Inc
  • 19.10. VistaGen Therapeutics, Inc

20 DISCLAIMER